Shruthi Kandalai

Shruthi Kandalai

Auto-generated profile, based on publicly available information

Shruthi Kandalai

Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2023 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
XZXiaozhuang Zhou
Xiaozhuang Zhou
NZNan Zhang
Nan Zhang
SKShruthi Kandalai
Shruthi Kandalai
HLHuapeng Li
Huapeng Li
FHFarzana Hossain
Farzana Hossain
Qingfei ZhengQingfei Zheng
Qingfei Zheng

16 October 2022 in Molecules
Verified
Journal Article
Open access
PDF file
FHFarzana Hossain
Farzana Hossain
SKShruthi Kandalai
Shruthi Kandalai
XZXiaozhuang Zhou
Xiaozhuang Zhou
NZNan Zhang
Nan Zhang
Qingfei ZhengQingfei Zheng
Qingfei Zheng
Cancer vaccines have been considered promising therapeutic strategies and are often constructed from whole cells, attenuated pathogens, carbohydrates, peptides, nucleic acids, etc. However, the use of whole organisms or pathogens can elicit unwanted immune responses arising from unforeseen reactions to the vaccine components. On the other hand, synthetic vaccines, which contain antigens that are conjugated, often with carrier proteins, can overcome these issues. Therefore, in this review we have highlighted the synthetic approaches and discussed several bioconjugation strategies for developing antigen-based cancer vaccines. In addition, the major synthetic biology approaches that were used to develop genetically modified cancer vaccines and their progress in clinical research are summarized here. Furthermore, to boost the immune responses of any vaccines, the addition of suitable adjuvants and a proper delivery system are essential. Hence, this review also mentions the synthesis of adjuvants and utilization of biomaterial scaffolds, which may facilitate the design of future cancer vaccines.

28 April 2025 in ASPET Discovery
Verified
Journal Article
Open access
TDThomas Drabison
Thomas Drabison
YXYue Xu
Yue Xu
EAEman A. Ahmed
Eman A. Ahmed
JSJack C. Stromatt
Jack C. Stromatt
NCNathan Colasanti
Nathan Colasanti
EEEric Daniel Eisenmann
Eric Daniel Eisenmann
This investigation compares paclitaxel pharmacokinetics using 7 strains of mice and 2 routes of administration and longitudinally explores pharmacodynamics using 2 representative strains, which informs cross-study comparisons and the validation of translationally relevant model systems. These findings support the notion that accumulation within dorsal root ganglia, rather than plasma exposure, is correlated with the development of peripheral neuropathy. This insight is anticipated to guide the future development of effective therapeutic strategies for managing paclitaxel-induced peripheral neuropathy.

4 February 2025 in Journal of Proteome Research
Verified
Journal Article
Closed access
HZHuan Zhang
Huan Zhang
SKShruthi Kandalai
Shruthi Kandalai
HPHaidong Peng
Haidong Peng
RXRui Xu
Rui Xu
MGMichael Geiman
Michael Geiman
JIANGJIANG (Chris) ZhuJIANGJIANG (Chris) Zhu
JIANGJIANG (Chris) Zhu